| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Carolina Costola-de-Souza, Alison Ribeiro, Viviane Ferraz-de-Paula, Atilio Sersun Calefi, Thiago Pinheiro Arrais Aloia, João Antonio Gimenes-Júnior, Vinicius Izidio de Almeida, Milena Lobão Pinheiro, João Palermo-Net. Monoacylglycerol lipase (MAGL) inhibition attenuates acute lung injury in mice. PloS one. vol 8. issue 10. 2014-08-05. PMID:24204926. |
thus, jzl184 increases the levels of 2-ag, an endocannabinoid that acts on the cb1 and cb2 cannabinoid receptors. |
2014-08-05 |
2023-08-12 |
mouse |
| Bruno A Marichal-Cancino, Guadalupe Manrique-Maldonado, Alain H Altamirano-Espinoza, Inna Ruiz-Salinas, Abimael González-Hernández, Antoinette Maassenvandenbrink, Carlos M Villaló. Analysis of anandamide- and lysophosphatidylinositol-induced inhibition of the vasopressor responses produced by sympathetic stimulation or noradrenaline in pithed rats. European journal of pharmacology. vol 721. issue 1-3. 2014-07-15. PMID:24076186. |
the endocannabinoid system exhibits multiple functions in cardiovascular regulation mainly by cannabinoid (cb1 and cb2) receptors, vanilloid trpv1 receptors and, probably, by the orphan g protein-coupled receptor 55 (gpr55). |
2014-07-15 |
2023-08-12 |
rat |
| Girish R Chopda, V Kiran Vemuri, Rishi Sharma, Ganesh A Thakur, Alexandros Makriyannis, Carol A Paroni. Diuretic effects of cannabinoid agonists in mice. European journal of pharmacology. vol 721. issue 1-3. 2014-07-15. PMID:24099963. |
in other studies, agonist injections were preceded by pretreatment with cannabinoid cb1 or cb2 selective antagonists, including a peripherally constrained cb1 antagonist. |
2014-07-15 |
2023-08-12 |
mouse |
| Kevin T Fitzgerald, Alvin C Bronstein, Kristin L Newquis. Marijuana poisoning. Topics in companion animal medicine. vol 28. issue 1. 2014-07-10. PMID:23796481. |
there are two specific cannabinoid receptors in humans and dogs, cb1 (primarily in central nervous system) and cb2 (peripheral tissues). |
2014-07-10 |
2023-08-12 |
human |
| Sabatino Maione, Barbara Costa, Vincenzo Di Marz. Endocannabinoids: a unique opportunity to develop multitarget analgesics. Pain. vol 154 Suppl 1. 2014-07-03. PMID:23623250. |
after 4 millennia of more or less documented history of cannabis use, the identification of cannabinoids, and of Δ(9)-tetrahydrocannabinol in particular, occurred only during the early 1960s, and the cloning of cannabinoid cb1 and cb2 receptors, as well as the discovery of endocannabinoids and their metabolic enzymes, in the 1990s. |
2014-07-03 |
2023-08-12 |
Not clear |
| Miquel Bioque, Borja García-Bueno, Karina S Macdowell, Ana Meseguer, Pilar A Saiz, Mara Parellada, Ana Gonzalez-Pinto, Roberto Rodriguez-Jimenez, Antonio Lobo, Juan C Leza, Miguel Bernard. Peripheral endocannabinoid system dysregulation in first-episode psychosis. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 38. issue 13. 2014-07-01. PMID:23822951. |
protein expression of cannabinoid receptor 2 (cb2), the protein levels of the main endocannabinoid synthesizing enzymes n-acyl phosphatidylethanolamine phospholipase (nape) and diacylglycerol lipase (dagl), and of degradation enzymes fatty acid amide hydrolase (faah) and monoacylglycerol lipase (magl) were determined by western blot analysis in peripheral blood mononuclear cells (pbmcs). |
2014-07-01 |
2023-08-12 |
human |
| Marylou V Solbrig, Yijun Fan, Paul Hazelto. Prospects for cannabinoid therapies in viral encephalitis. Brain research. vol 1537. 2014-06-25. PMID:24021420. |
using a rodent model of chronic viral encephalitis based on borna disease (bd) virus, in which 1 week treatment with the general cannabinoid win 55,212-2 has been shown to be neuroprotective (solbrig et al., 2010), we examine longer term (2 week treatment) effects of a general (cb1 and cb2) cannabinoid receptor agonist win55,212-2 (1mg/kg ip twice per day) or a specific (cb2) cannabinoid receptor agonist hu-308 (5mg/kg ip once daily) on histopathology, measures of frontostriatal neurogenesis and gliogenesis, and viral load. |
2014-06-25 |
2023-08-12 |
rat |
| Marylou V Solbrig, Yijun Fan, Paul Hazelto. Prospects for cannabinoid therapies in viral encephalitis. Brain research. vol 1537. 2014-06-25. PMID:24021420. |
the selective cb2 agonist hu increases brdu(+) cells in prefrontal cortex (pfc), significantly increases brdu(+) cells in striatum, differentially regulates polydendrocytes vs. microglia/macrophages, and reduces immune activation at a time win-treated rats appear tolerant to the anti-inflammatory effect of their cannabinoid treatment. |
2014-06-25 |
2023-08-12 |
rat |
| Marylou V Solbrig, Yijun Fan, Paul Hazelto. Prospects for cannabinoid therapies in viral encephalitis. Brain research. vol 1537. 2014-06-25. PMID:24021420. |
thus, hu-308 action on cb2 receptors, receptors known to be renewed during microglia proliferation and action, is a nontolerizing mechanism of controlling cns inflammation during viral encephalitis by reducing microglia activation, as well as partially limiting viral infection, and uses a nonpsychotropic cannabinoid agonist. |
2014-06-25 |
2023-08-12 |
rat |
| Sofia Sisay, Gareth Pryce, Samuel J Jackson, Carolyn Tanner, Ruth A Ross, Gregory J Michael, David L Selwood, Gavin Giovannoni, David Bake. Genetic background can result in a marked or minimal effect of gene knockout (GPR55 and CB2 receptor) in experimental autoimmune encephalomyelitis models of multiple sclerosis. PloS one. vol 8. issue 10. 2014-06-24. PMID:24130809. |
endocannabinoids and some phytocannabinoids bind to cb1 and cb2 cannabinoid receptors, transient receptor potential vanilloid one (trpv1) receptor and the orphan g protein receptor fifty-five (gpr55). |
2014-06-24 |
2023-08-12 |
mouse |
| Thangesweran Ayakannu, Anthony H Taylor, Timothy H Marczylo, Jonathon M Willets, Justin C Konj. The endocannabinoid system and sex steroid hormone-dependent cancers. International journal of endocrinology. vol 2013. 2014-06-24. PMID:24369462. |
the "endocannabinoid system (ecs)" comprises the endocannabinoids, the enzymes that regulate their synthesis and degradation, the prototypical cannabinoid receptors (cb1 and cb2), some noncannabinoid receptors, and an, as yet, uncharacterised transport system. |
2014-06-24 |
2023-08-12 |
Not clear |
| Ester Aso, Isidre Ferre. Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic. Frontiers in pharmacology. vol 5. 2014-06-24. PMID:24634659. |
the endocannabinoid system is composed by a number of cannabinoid receptors, including the well-characterized cb1 and cb2 receptors, with their endogenous ligands and the enzymes related to the synthesis and degradation of these endocannabinoid compounds. |
2014-06-24 |
2023-08-12 |
Not clear |
| Alexei A Yelisee. Methods for recombinant expression and functional characterization of human cannabinoid receptor CB2. Computational and structural biotechnology journal. vol 6. 2014-06-24. PMID:24688719. |
cb2 is a part of the endocannabinoid system that plays vital role in regulation of immune response, inflammation, pain sensitivity, obesity and other physiological responses. |
2014-06-24 |
2023-08-12 |
human |
| Ismael Galve-Roperh, Valerio Chiurchiù, Javier Díaz-Alonso, Monica Bari, Manuel Guzmán, Mauro Maccarron. Cannabinoid receptor signaling in progenitor/stem cell proliferation and differentiation. Progress in lipid research. vol 52. issue 4. 2014-06-20. PMID:24076098. |
the latter is an ensemble of endogenous lipids, their receptors [in particular type-1 (cb1) and type-2 (cb2) cannabinoid receptors] and metabolic enzymes. |
2014-06-20 |
2023-08-12 |
human |
| Laurent Hortala, Joëlle Arnaud, Pascale Roux, Didier Oustric, Laurent Boulu, Florence Oury-Donat, Patrick Avenet, Thomas Rooney, David Alagille, Olivier Barret, Gilles Tamagnan, Francis Bart. Synthesis and preliminary evaluation of a new fluorine-18 labelled triazine derivative for PET imaging of cannabinoid CB2 receptor. Bioorganic & medicinal chemistry letters. vol 24. issue 1. 2014-06-12. PMID:24291040. |
synthesis and preliminary evaluation of a new fluorine-18 labelled triazine derivative for pet imaging of cannabinoid cb2 receptor. |
2014-06-12 |
2023-08-12 |
monkey |
| Laurent Hortala, Joëlle Arnaud, Pascale Roux, Didier Oustric, Laurent Boulu, Florence Oury-Donat, Patrick Avenet, Thomas Rooney, David Alagille, Olivier Barret, Gilles Tamagnan, Francis Bart. Synthesis and preliminary evaluation of a new fluorine-18 labelled triazine derivative for PET imaging of cannabinoid CB2 receptor. Bioorganic & medicinal chemistry letters. vol 24. issue 1. 2014-06-12. PMID:24291040. |
cannabinoid cb2 pet tracers are considered as a promising alternative to pbr/tspo tracers for the in-vivo imaging of neuroinflammation. |
2014-06-12 |
2023-08-12 |
monkey |
| Jarogniew J Luszczki, Marta Andres-Mach, Beata Barcicka-Klosowska, Magdalena Florek-Luszczki, Agnieszka Haratym-Maj, Stanislaw J Czuczwa. Effects of WIN 55,212-2 mesylate (a synthetic cannabinoid) on the protective action of clonazepam, ethosuximide, phenobarbital and valproate against pentylenetetrazole-induced clonic seizures in mice. Progress in neuro-psychopharmacology & biological psychiatry. vol 35. issue 8. 2014-06-09. PMID:21777642. |
the aim of this study was to determine the effect of win 55,212-2 mesylate (win - a non-selective cannabinoid cb1 and cb2 receptor agonist) on the protective action of four classical antiepileptic drugs (aeds: clonazepam [czp], ethosuximide [ets], phenobarbital [pb], and valproate [vpa]) in the mouse pentylenetetrazole (ptz)-induced clonic seizure model. |
2014-06-09 |
2023-08-12 |
mouse |
| Mahmoud Fahmi Elsebai, Viktor Rempel, Gregor Schnakenburg, Stefan Kehraus, Christa E Müller, Gabriele M Köni. Identification of a Potent and Selective Cannabinoid CB1 Receptor Antagonist from Auxarthron reticulatum. ACS medicinal chemistry letters. vol 2. issue 11. 2014-06-05. PMID:24900275. |
in radioligand binding studies at human cannabinoid cb1 and cb2 receptors recombinantly expressed in chinese hamster ovary (cho) cells, amauromine (1) was found to exhibit high affinity and selectivity for the cb1 receptor (k i = 178 nm). |
2014-06-05 |
2023-08-13 |
human |
| Viktor Rempel, Alexander Fuchs, Sonja Hinz, Tadeusz Karcz, Matthias Lehr, Uwe Koetter, Christa E Mülle. Magnolia Extract, Magnolol, and Metabolites: Activation of Cannabinoid CB2 Receptors and Blockade of the Related GPR55. ACS medicinal chemistry letters. vol 4. issue 1. 2014-06-05. PMID:24900561. |
magnolia extract, magnolol, and metabolites: activation of cannabinoid cb2 receptors and blockade of the related gpr55. |
2014-06-05 |
2023-08-13 |
Not clear |
| Francisco Navarrete, Marta Rodríguez-Arias, Elena Martín-García, Daniela Navarro, María S García-Gutiérrez, María A Aguilar, Auxiliadora Aracil-Fernández, Pere Berbel, José Miñarro, Rafael Maldonado, Jorge Manzanare. Role of CB2 cannabinoid receptors in the rewarding, reinforcing, and physical effects of nicotine. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 38. issue 12. 2014-06-03. PMID:23817165. |
role of cb2 cannabinoid receptors in the rewarding, reinforcing, and physical effects of nicotine. |
2014-06-03 |
2023-08-12 |
mouse |